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Abstract
The shift in nutritional sciences from survival and safety to the promotion of well-being has led to sys-
tematic investigations on the biological activity of natural products of dietary origin, questioning the
assumption that food plants contain little if any secondary metabolites apart those revealed by our senses
and responsible for their colour, taste, and ﬂavour. With 25% of the human population consuming chilli
pepper every day, capsaicin is the most important pharmacological agent we get from our diet, and the
study of its pungency set in motion a multidisciplinary investigation that ultimately led to the discovery of
vanilloid receptors (TRPVs), a class of ion channels involved in thermo-, chemo-, and mechanosensation,
and whose malfunctioning is implicated in neurogenic inﬂammation and a host of other pathological
conditions. A series of studies centred on the modiﬁcation of capsaicin will be described, focusing on a) the
preparation of a library of unnatural natural capsaicinoids and the identiﬁcation of leads with the lipophilic
C-moiety amenable to structure-activity study, and b) the reversal of the biological activity of capsaicin
from a TRPV1 agonist into an antagonist by modiﬁcation of its vanillyl moiety.
Abbreviations: AE – Arachidonoylethanolamine (=Anandamide); COX-1 (2) – Cyclooxygenase-1 (2); CPS
– Capsaicin; GRAS List – Generally Recognized as Safe List; NADA – N-Arachidonoyldopamine; NSAID
– Non Steroid Anti-Inﬂammatory Drug; OLDA – N-Oleoyldopamine; PABA – para-Aminobenzoic Acid;
PPAA – Prophyl Phosphonic Acid Anhydride; RTX – Resiniferatoxin; SERCA – Sarcoendoplasmatic
Reticulum Ca(II) ATPase; TRPV – Transient Receptor Potential Vanilloid
Introduction
The modern clinical trial was ﬁrst described in the
Bible (Daniel, 1), but only carried out 2000 years
later by the navy surgeon James Lind as part of a
study on the prevention of scurvy (Appendino and
Taglialatela- Scafati, 2003c). Several explanations
have been given as to why medicine was so slow to
adopt the scientiﬁc method (Sneader, 1996). Nev-
ertheless, edible- and not medicinal plants were
used in both cases (legumes and Citrus fruits,
respectively). This observation is hardly surprising,
since medicine and nutrition have long shaded into
each other. Their divorce is essentially a modern
artefact, since in all cultures a considerable share
of food plants have also been used in traditional
medicine (Pieroni et al., 2002). Scouring the planet
for the most exotic and expensive remedies has
always been a sort of fashionable trend in natural
products chemistry, even ﬁnding its way into the
plot of a successful Hollywood movie (Medicine
Man, directed by J. McTieman and starring Sean
Connery, 1992). Food plants are trivial, easily
available, and generally contain low concentration
of secondary metabolites. Unsurprisingly, they
were long overlooked as a source of bioactive
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compounds. However, over the past decades, there
has been a growing awareness that food plants,
apart from macronutrients (proteins, lipids, sug-
ars) and essential micronutrients (vitamins, min-
erals) also contain secondary metabolites that can
play a role in the maintenance of human health.
This has led to a shift in nutritional sciences from
survival and safety to the promotion of well-being,
challenging the long-held assumption that food
plants contain little if any secondary metabolites
apart those revealed by our senses and responsible
for their colour, taste, and ﬂavour.
There is currently no comprehensive review or
book on the chemistry and biochemistry of sec-
ondary metabolites from food plants. This article,
while highlighting the relevance of the subject,
will essentially summarise recent results on a
single class of compounds (capsaicinoids). Though
undoubtedly limiting, the examples discussed are
nevertheless paradigmatic for the problems facing
research in this ﬁeld.
Food plants as a source of drugs, drug leads, and
unusual secondary metabolites
Scouring the refrigerator or the cupboard for
drugs leads might sound naı¨f in the age of -omic
sciences, but this is the origin of statins. With an-
nual sales over 15 billion dollars, statins are the
commercially most successful drugs ever, and
lovastatin (1) is their archetypal member. This
compound was ﬁrst isolated from the red yeast of
rice, an ingredient of the oriental cuisine used to
give the red colour and typical taste to the Peki-
nese duck, and this dietary origin has caused long
and bitter legal litigation between the pharma-
ceutical- and the health food industries (Journoud
and Jones, 2004). Statins are structurally unique
compounds. They belong to the rare class of nat-
urally occurring Diels-Alder adducts, and exem-
plify how our diet can be a real treasure throve of
structurally unique and biologically active sec-
ondary metabolites. Another remarkable example
is the occurrence of triterpene p-aminobenzoates
(exempliﬁed by 2) in the seeds of pumpkin and
related plants (courgettes, cucumber, melon, water
melon) (Appendino et al., 2000). Nature is rather
conservative in the use of key metabolites, and the
proﬂigacy by which these plants accumulate esters
of PABA in their seeds is unprecedented in living
organisms, as is the occurrence of nonprenylated
oligomeric phloroglucinols like 3 in the leaves of
myrtle (Appendino et al., 2002a). While no bio-
activity has so far been reported for pumpkin
p-aminobenzoates, the oligomeric phloroglucinols
from myrtle show a remarkable antibacterial
activity, especially against super bugs (Appendino
et al., 2002a). Myrtle is just one of the over 150
plants included in the GRAS (Generally Recog-
nized As Safe) list of herbal ingredient for liqueurs
(Duke, 1987). Many of these plants have never
been investigated for their non-volatile constitu-
ents, and there is no shortage of interest for this
matter, as shown by the fascinating correlation
between the chromatic aberrations by van Gogh
and the presence of santonin-like compounds in
wormwood (Artemisia absinthium L.) (Arnold,
1992). a-Santonin (4) was once used in medicine as
an anthelmintic drug, and can change the way
colours are perceived, turning vision to yellow.
Wormwood does not contain a-santonin, but the
extremely bitter dimeric guaianolide absinthin (5),
whose pharmacology is still totally unknown.
Structurally unusual bitter sesquiterpene lactones
are also contained in other plants used for the
production of liqueurs, as exempliﬁed by the per-
oxides 6 and 7 from mountain wormwood
(A. umbelliformis Lam) (Appendino et al., 1983)
and from curly tansy (Tanacetum vulgare L. var.
crispum Fiori) (Appendino et al., 1982), two plants
used for the production of alpine liqueurs (Genepy
and Chartreuse, respectively).
The kitchen connection. Vanilloid receptors as anti-
inﬂammatory targets
No compound better than capsaicin (CPS, 8)
exempliﬁes the blurred boundaries between food
and medicine. With 25% of the human population
consuming chilli pepper every day, 8 is the most
important pharmacological agent we get from our
diet (Szallasi and Blumberg, 1999), and the study
of its pungency set in motion a multidisciplinary
investigation that ultimately led to the discovery of
vanilloid receptors (TRPVs). These ion channels
are involved in thermo-, chemo-, mechanosensa-
tion, and their malfunctioning is involved in neu-
rogenic inﬂammation, and, possibly, in other
pathological conditions as well (Szallasi and
Blumberg, 1999).
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Capsaicin was ﬁrst isolated in 1876, structurally
elucidated in 1919, and ﬁrst synthesised in 1930
(Szallasi & Blumberg, 1999). Despite all this
chemical activity, it was ignored by pharmacolo-
gists for a long time, probably because too
obnoxious to handle. Things changed in 1989,
when an ultrapotent analogue was discovered, the
phorboid resiniferatoxin (RTX, 9a) (Szallasi and
Blumberg, 1989). By using radioactive RTX, it was
possible to demonstrate a speciﬁc binding of cap-
saicin to nerve membranes, and this set in motion
an intense research activity that culminated eight
years later in the characterisation of a thermore-
ceptor speciﬁcally activated by CPS. Since 8 and 9
share a vanillyl moiety, this receptor was named
the vanilloid receptor (VR1), but is now better
known as TRPV1 (for a recent review, see:
Appendino et al., 2003b). In 2000, knock-out mice
for TRPV1 were created by genetic engineering.
This animals showed an impaired pain sensation,
but were otherwise normal, an observation that
validated TRPV1 as a pharmacological target.
Four further vanilloid receptors were cloned in the
years 2000–2003. Though structurally related to
TRPV-1, these receptors (TRPV-2/TRPV-5) do
not bind capsaicin, nor does the avian and version
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of TRPV1 (Appendino et al., 2003). TRPV1 is a
heat-sensitive ion channel whose activation
threshold is lowered by an increase of temperature,
a decrease of pH, as well as by capsaicin and an
heterogenous group of compounds named vanil-
loids. Activation is followed by a calcium inﬂux,
and is eventually translated into a painful stimulus
on the proximal ending of the nerve, while inﬂam-
matory peptides are secreted on the distal nerve
ending. Activation is followed by a long lasting
refractory state known as desensitisation, a partic-
ular form of analgesia where only pain sensitivity is
lost, and a unique property that makes capsaicin
diﬀerent from all other oﬀensive agents. Vanilloid
receptors are also expressed in the central nervous
system, where temperature and pH are constant,
and where receptor activation is provided by a
series of lipid-derived endogenous compounds
known as endovanilloids by analogy with the
endogenous versions of opiodis and cannabinoids
(endorphins and endocannabinoids, respectively)
(Di Marzo et al., 2002). While anandamide (AE,
10) and NADA (N-arachidonoyldopamide, 11a)
can also interact with cannabinoid receptors,
OLDA (N-Oleyldopamide, 11b) is more selective
for vanilloid receptors. The analgesic properties of
arachidoylated endovanilloids and endocannnabi-
noids might contribute to the beneﬁcial eﬀects of
non-steroideal antiinﬂammatory drugs. By inhibit-
ing COX-enzymes, these compounds might in fact
redirect the metabolism of arachidonic acid from
inﬂammatory prostanoids to anti-inﬂammatory
fatty amides like AE and NADA. Alternatively, the
inhibition of COXs might shut down one major
way of degradation of AE ane NADA (Fowler,
2004). A more direct involvement was suggested for
acetaminophen (12a), the most successful NSAID.
This compound does not inhibit COX-1or COX-2,
but is deacetylated and arachidonoylated in the
brain, aﬀording AM-404 (12b), a known inhibitor
of anandamide degradation, and a powerful acti-
vator of TRPV1 and inhibitor of COX-1 and
COX-2 (Hogestatt, 2003).
CPS-sensitive neurones are bi-modal. Besides
the classical aﬀerent algogenic function, they also
have local eﬀerent function, secreting neuropep-
tides that sustain a series of pathophysiological
changes (vasodilatation, plasma protein extrava-
sation, accumulation of inﬂammatory cells) that
trigger neurogenic inﬂammation, a process in-
volved several pathological conditions (rheuma-
toid arthritis, migraine, asthma, psoriasis, allergic
rhinitis) whose current management is either
modest or non-existing.
The inhibition of capsaicin-sensitive nerves is a
logical approach to contrast neurogenic inﬂam-
mation, and is an important pharmacological
target (Szallasi and Appendino, 2004). There are
two basic strategies to accomplish this. The ﬁrst
one is desensitisation, a long-lasting process, pos-
sibly mediated by phosphorylation, typical of
TRPV-1 agonists. The second one is classical
antagonism, namely the interference with the
activation from agonists (low pH, endovanilloids).
We pursued both of them.
The development of a library of unnatural natural
capsaicinoids
There is no shortage of activators of TRPV1
within the pool of natural products (Appendino
et al., 2003), but capsaicinoids are those better
investigated and more accessible from a synthetic
standpoint. For structure-activity studies, capsai-
cin has been traditionally divided into three
moieties, the aromatic A-region, the lipophilic
C-region and the amide B-linker (see 8). While the
A and B regions have been thoroughly investi-
gated, the lipophilic C-region is not, because of its
poverty of functional groups (the branching and
the unsaturation, both redundant for biological
activity) and because of its conformational ﬂexi-
bility (rotation is possible around eight sigma C–C
bonds). Capsacin is not therefore a suitable probe
to investigate the eﬀect of changes on the C-region,
while an ideal lead should have this region deco-
rated with functional groups non redundant in
terms of biological activity, and versatile from the
viewpoint of chemical manipulation.
In search for a convenient surrogate for cap-
saicin, we turned to Nature and got inspiration
from its unmatched capacity to generate chemical
diversity. The process of drug discovery has been
compared to a lottery. In this lottery, natural
products are special tickets, but are few and diﬃ-
cult to get. So, we turned to surrogate natural
products, or ‘unnatural’ natural products
(Appendino et al., 2001). The branched short fatty
acid of CPS is found exclusively in plants from the
genus Capsicum, but a host of fatty- and isopren-
oid acids are easily available from the natural
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products pool. Acylation of vanillamine with these
acids would aﬀord unnatural (as regards occur-
rence) natural (as regards the origin of their
building blocks) capsaicinoids. Nature has deftly
exploited this strategy, and its view as a molecular
tinkerer should be credited to Franc¸ois Jacob. In a
seminal conference on evolution held at Berkeley
University, Jacob remarked that ‘natural selection
works like a tinkerer who does not known exactly
what he is going to produce but uses whatever he
ﬁnds around him to produce some kind of workable
object. None of the material at the tinkerer’s disposal
has a precise and deﬁnite function. Each can be used
in diﬀerent ways. Novelty comes from previously
unseen associations of old materials. To create is to
recombine’ (Jacob, 1977).
Vanillamine is a phenolic amine, and to
implement our strategy we ﬁrst had to solve a
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synthetic problem, since the acylation of phenolic
amines shows low chemoselectivity with diimides,
while activation via chlorides or mixed anhydrides
is diﬃcult with polyunsaturated and hydroxylated
acids. To solve this problem, we developed an
alternative protocol based on the in situ formation
of mixed phosphoric anhydrides by treatment of
acids with PPAA (propyl phosphonic acid anihy-
dride, 13). Compared to other condensing agents,
PPAA is chemoselective for amino groups vs
phenolic hydroxyls, and shows also a series of
practical advantages, being cheap, relatively non
toxic, easy to store, and essentially traceless, giving
only water-soluble by-products (Appendino et al.,
2002b). Having solved the synthetic problem, we
could easily assemble a small library of unnatural
natural capsaicinoids made from fatty acids as well
acyclic, monocyuclic and polycyclic terpenoid
acids. All compounds were assayed for vanilloid
activity in cells transfected with h-TRPV1, mea-
suring eﬃciency and potency. Three compounds
emerged as powerful vanillloid ligands, over ten-
fold more active than capsaicin, namely the va-
nillamides of ricinoleic acid, retinoic acid, and
farnesic acids (rinvanil (14a), retvanil (14b), and
farnvanil (14c), respectively). Using fatty acyl va-
nillamides, some interesting insights on the rec-
ognition site for the lipophilic moiety of
capsaicinoids could be obtained. Thus, while the
vanillamide of stearic acid (14d) was essentially
inactive, that of oleic acid (olvanil, 14e) was more
potent than capsaicin, showing that the double
bond is critical for activity. Since the double bond
could be replaced by a cyclopropane ring, its role
is apparently conformational. Furthermore, hy-
droxy groups could be easily accommodated into
the lipophilic moiety, as shown by the powerful
activity of rinvanil (14a). The presence of a sec-
ondary hydroxyl on the C-region of this com-
pound gives the opportunity for a variety of
modiﬁcation, currently actively pursued with the
hope of improving the unnatural natural lead.
The taming of capsaicin
While the presence of oﬀensive compounds within
the pool of natural products is somewhat logical,
secondary metabolites being essentially chemical
weapons, the existence of vanilloid antagonists is
apparently counterintuitive. The sesquiterpene
lactone thapsigargicin (15) is the only known
natural inhibitor of TRPV1 (Toth et al., 2002).
This highly obnoxious, oﬀensive, and tumour-
promoting guaianolide is a known activators of
sarcoplasmatic reticulum Ca2+-ATPases (SER-
CAs), and it is not clear to what extent vanilloid
antagonism can be dissected from this activity.
Furthermore, thapsigargicin is structurally com-
plex, diﬃcult to obtain by isolation, and not easily
amenable to total synthesis. A serendipitous
observation at Novo-Nordisk paved the way to a
diﬀerent approach to get vanilloid antagonists
from the natural products pool, namely the ago-
nist-to-antagonist swap (Wahl et al., 2001). Thus,
while attempting to prepare a radioactive version
of RTX (9a), it was discovered that iodination
ortho to the phenolic hydroxyl (C-5¢) reverted the
biological activity of the natural product, turning
it into a powerful vanilloid antagonist (9b). Fur-
ther studies at Johnson & Johnson conﬁrmed these
ﬁnding, and also disclosed that iodination at C-6¢
could generate a partial agonist (McDonnel et al.,
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2002). RTX is not commercially available in syn-
thetically useful amounts, and a comprehensive
investigation on the eﬀect of aromatic substitution
could not be carried out on this compound. On the
other hand, synthetic capsaicin (nonivamide, N-
nonanoylvanillammine, 16) is commercially avail-
able, and we used this compound to assess these
points. All three iodinated forms of nonivamide
were synthesized. While the 2-iododerivative (17)
lacked aﬃnity for TRPV1, both the 5- and the
6-iododerivatives (18 and 19, respectively) showed
antagonist activity, potency being higher for C-6
rather than C-5 iodination (Appendino et al.,
2003a). The antagonistic potency was dependent
not only on the location of the halogen group, but
also on its nature, since, both for C-5 and C-6
substitution, the bromo- and chloro analogues
were less potent than their parent iodinated
derivatives. Replacement of the 6-iodo group with
various carbon susbstituents (ethyl, ethenyl, ethy-
nyl, acetyl) gave vanilloid antagonists less potent
that the iododerivative 19. Compared to capsaze-
pine, the standard capsaicinoid antagonist, 6-iod-
ononivamide (19) is easier to synthesise (three
steps from a commercial product) and more potent
(ca. 2-fold). Furthermore, it seems reasonable to
assume that the optimisation of the acyl moiety in
terms of aﬃnity could be combined with that of
the vanillyl moiety in terms of antagonism, gen-
erating even more powerful TRPV1 antagonists
with capsaicinoid structure.
Conclusions
Despite investigations spanning over a century,
capsaicin is still a versatile lead compound for
induction and modulation of bioactivity. The
capsaicinoid template has provided inspiration for
the discovery of new potent TRPV1 agonists and
antagonists, paving the way to the development of
new compounds aimed at contrasting neurogenic
inﬂammation by desensitisation or pharmacologi-
cal antagonism of TRPV1. Capsaicin is not the
only clinically-validated antiinﬂammatory com-
pound of dietary origin, nor is the only TRPV1
agonist that hot cuisine has provided to the bio-
medical research. A search on the Drugs of the
Future database evidenced other dietary leads
undergoing clinical development as anti-inﬂam-
matory agents (luteoline, quercetine, salicilic acid,
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curcumine) (Appendino and Taglialatela-Scafati,
2003c), while the sesquiterpene dialdehydes po-
lygodial (20), the alkaloid piperine (21) and the
prenylated phenol scutigeral (22) are examples of
non-capsaicinoid TRPV1 activators of dietary
origin (Sterner and Szallasi, 1999).
If food plants contain such a wealth of biolog-
ically active compounds, then there is also a ﬂip
side of the coin, related to the poverty in plant
diversity of modern diet. Western diet is based on
few domesticated plants bred for yield and succu-
lence rather than biochemistry variety, and by
adopting it, we are ‘missing something’. Our diet is
pharmacologically impoverished, being deprived of
a host of ‘quasi-vitamins’ that our physiology has
evolved to make us of. Cheap fats-and-sugars rich
food, large portions, and persuasive advertisement
have changed our diet, in a way whose impact on
health is impossible to study in any kind of rigorous
controlled scientiﬁc trial, but nevertheless worth
considering. We are living in a toxic food environ-
ment, and, if nothing is done against the fast-food
culture that sweeps youth ‘for the ﬁrst time in a
hundred years, life expectancy will actually go down’
(Krebs, 2003). Knowledge about food plants is
disappearing rapidly, and local culinary traditions
are rapidly becoming ‘exotic’. We do not need to
travel to the tropic to see a massive loss of biodi-
versity, a look into our dish will probably suﬃce.
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